Shaping the future of precision oncology
From diagnosis through survivorship, supporting patients across the continuum of care.
From detection to decision-making
Featured oral and poster presentations across the continuum of care, including the latest Signatera evidence.
Experience Annotation
Complete longitudinal context at a glance, quickly identify high-priority Signatera positive cases.
Precision Oncology Solutions
Natera’s leading precision oncology portfolio: Signatera, Altera, Latitude, and Empower.
From detection to decision-making
Featured research across the continuum of care, from diagnosis through survivorship.
Complete longitudinal
context at a glance
Quickly identify high-priority Signatera™ positive cases.
-
1
Longitudinal context, at a glance
View ctDNA trajectories layered with clinical milestones: diagnosis, surgery, therapy response.
-
2
Molecular and clinical data, layered
Annotate Signatera™ results with imaging, pathology, and treatment events.
-
3
Surface trends faster
Identify molecular relapse and prioritize follow-up across your patient panel.
*Case shown is for illustrative purposes only.
Natera's leading precision oncology portfolio
A complete suite of solutions across the continuum of care, built on the most extensively validated and published MRD assay.
Ultrasensitive high-fidelity MRD
Signatera™
Residual disease test (MRD)
Most extensively studied, adopted, and reimbursed MRD assay available.
Latitude™
Tissue-free MRD test
Qualitative sensitivity, even when tissue is limited.
Genomic profiling & hereditary risk
Altera™
Tumor genomic profile
Identify clinically actionable tumor biomarkers to support optimal treatment planning.
Empower™
Hereditary cancer test
Detect inherited genetic mutations to guide personalized care & familial risk assessment.
From detection to decision-making
Detect residual disease
Identify ctDNA after definitive treatment, before radiographic evidence.
Optimize treatment
Guide escalation, de-escalation, and adjuvant decisions on patient relapse risk.
Monitor over time
Track response and disease burden across therapy lines with serial measurements.
Identify relapse earlier
Surface molecular relapse months ahead of standard-of-care imaging.
Visit Natera at booth 14046
Supporting patients across the continuum of care from diagnosis through survivorship.
Visit us at McCormick Place, Hall A, May 29–June 2.
Live product demonstrations
Hands-on with Annotation, Signatera™ reports, and Latitude™.
Clinical discussions with experts
Drop-in conversations with our medical and scientific team throughout the meeting.
New data, posters, and abstracts
Featured research across CRC, breast, GU, lung, lymphoma, melanoma, and more.
Connect with our team
Personalized testing can help answer important questions after a cancer diagnosis. Tell us a bit about you and a member of our team will follow up.